![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 1
Zeitschriftenartikel
DeTemple, Viola K. 
ORCID: https://orcid.org/0000-0001-6246-8862; Kaatz, Martin ORCID: https://orcid.org/0000-0002-0650-2576; Stockfleth, Eggert; Scheel, Christina; Angela, Yenny ORCID: https://orcid.org/0000-0002-6643-7286; Gutzmer, Ralf ORCID: https://orcid.org/0000-0001-7921-2820; Leiter, Ulrike; Meier, Friedegund ORCID: https://orcid.org/0000-0003-4340-9706; Schadendorf, Dirk ORCID: https://orcid.org/0000-0003-3524-7858; Livingstone, Elisabeth ORCID: https://orcid.org/0000-0001-8279-9239; Gebhardt, Christoffer ORCID: https://orcid.org/0000-0001-7090-9584; Wasielewski, Imke von; Weichenthal, Michael ORCID: https://orcid.org/0000-0002-9060-4961; Mohr, Peter; Hassel, Jessica ORCID: https://orcid.org/0000-0001-7575-6230; Pföhler, Claudia ORCID: https://orcid.org/0000-0003-0384-114X; Simon, Jan Christoph; Jochims, Franziska ORCID: https://orcid.org/0000-0003-2279-2072; Terheyden, Patrick; Ulrich, Jens; Haferkamp, Sebastian; Drexler, Konstantin; Schilling, Bastian; Glutsch, Valerie ORCID: https://orcid.org/0000-0001-9291-1327; Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643; Berking, Carola; Ugurel, Selma ORCID: https://orcid.org/0000-0002-9384-6704 und Tomsitz, Dirk ORCID: https://orcid.org/0000-0003-0036-072X
(2025):
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
In: European Journal of Cancer, Bd. 225, 115590
[PDF, 2MB]
ORCID: https://orcid.org/0000-0001-6246-8862; Kaatz, Martin ORCID: https://orcid.org/0000-0002-0650-2576; Stockfleth, Eggert; Scheel, Christina; Angela, Yenny ORCID: https://orcid.org/0000-0002-6643-7286; Gutzmer, Ralf ORCID: https://orcid.org/0000-0001-7921-2820; Leiter, Ulrike; Meier, Friedegund ORCID: https://orcid.org/0000-0003-4340-9706; Schadendorf, Dirk ORCID: https://orcid.org/0000-0003-3524-7858; Livingstone, Elisabeth ORCID: https://orcid.org/0000-0001-8279-9239; Gebhardt, Christoffer ORCID: https://orcid.org/0000-0001-7090-9584; Wasielewski, Imke von; Weichenthal, Michael ORCID: https://orcid.org/0000-0002-9060-4961; Mohr, Peter; Hassel, Jessica ORCID: https://orcid.org/0000-0001-7575-6230; Pföhler, Claudia ORCID: https://orcid.org/0000-0003-0384-114X; Simon, Jan Christoph; Jochims, Franziska ORCID: https://orcid.org/0000-0003-2279-2072; Terheyden, Patrick; Ulrich, Jens; Haferkamp, Sebastian; Drexler, Konstantin; Schilling, Bastian; Glutsch, Valerie ORCID: https://orcid.org/0000-0001-9291-1327; Heinzerling, Lucie ORCID: https://orcid.org/0000-0001-5718-3643; Berking, Carola; Ugurel, Selma ORCID: https://orcid.org/0000-0002-9384-6704 und Tomsitz, Dirk ORCID: https://orcid.org/0000-0003-0036-072X
(2025):
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
In: European Journal of Cancer, Bd. 225, 115590
[PDF, 2MB]